Skip to Content

Join the 'Lenvatinib' group to help and get support from people like you.

Lenvatinib News

More Patients OK'd for Cancer Trials Under Obamacare: Study

Posted 20 Jul 2017 by Drugs.com

THURSDAY, July 20, 2017 – The Affordable Care Act has enabled more privately insured patients to enroll in clinical trials for new cancer treatments, a new study contends. Speedy approvals are important for patients who want to participate in clinical trials, said study author Dr. David Hong. He's deputy chair of investigational cancer therapeutics at the University of Texas MD Anderson Cancer Center. Since 2000, Medicare, the publicly funded insurance program for seniors, has covered routine costs of clinical trial participation. But coverage for patients with private insurance differed by insurer and state, the researchers noted. Under the ACA, or Obamacare, however, private insurers had to cover "standard of care" costs of clinical trial participation as of 2014. For this study, the researchers analyzed more than 2,400 patient referrals to the Clinical Center for Targeted Therapy at ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Gleevec, Non-Small Cell Lung Cancer, Votrient, Tarceva, Avastin, Pancreatic Cancer, Tasigna, Sutent, Sprycel, Afinitor, Nexavar, Stomach Cancer, Carboplatin, Cisplatin, Cytoxan

Doctors' Group Offers Ideas for Easing Cancer Costs

Posted 19 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money woes. The proposals include allowing Medicare to negotiate drug prices, legalizing the importation of drugs, and adopting bundled, or group, payment programs. In the new policy statement, ASCO also says it supports creation of a panel of "stakeholders" in health care to determine the effectiveness of its proposals. Such a group might also outline a uniform approach for assessing the value of drugs. "In what, undoubtedly, is one of the most difficult times in their lives, individuals with cancer should be focused on getting the best care possible, not worrying about financial strain on their families," said Dr. Clifford Hudis. He's CEO of ASCO, a leading ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Femara, Lupron Depot, Lung Cancer, Colorectal Cancer, Gleevec, Zoladex, Votrient, Brain Tumor, Anastrozole

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Lung Cancer, Colorectal Cancer, Gleevec, Rituxan, Isotretinoin

For Seniors, Treatment for One Eye Disease May Cause Another

Posted 16 Mar 2017 by Drugs.com

THURSDAY, March 16, 2017 – Drugs that preserve vision in people with the eye disease called age-related macular degeneration might increase the risk of another eye condition – glaucoma, a new study suggests. People who received at least seven eye injections of the drug bevacizumab (Avastin) each year to treat macular degeneration have a higher risk of eventually needing surgery to treat glaucoma, the Canadian study found. But, the researchers aren't suggesting that people forgo these treatments for macular degeneration. These drugs help stave off a previously untreatable cause of blindness in the elderly, and should continue to be used, the researchers said. And, if glaucoma does develop, treatments are available. "Even though there may be a risk here, this doesn't mean you should not be getting injections for macular degeneration," said study lead author Dr. Brennan Eadie. He's an ... Read more

Related support groups: Eye Conditions, Glaucoma, Macular Degeneration, Glaucoma (Open Angle), Votrient, Avastin, Sutent, Nexavar, Pazopanib, Stivarga, Sunitinib, Retinal Disorders, Glaucoma/Intraocular Hypertension, Sorafenib, Cyramza, Bevacizumab, Retinopathy, Vandetanib, Cabometyx, Lenvima

Cancer's Heavy Financial Burden

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – Many cancer patients can't afford to see their doctor or take the medications they've been prescribed, a new study finds. And the problem will likely only get worse as the cost of cancer treatments continues to rise, the study authors said. "You can prescribe the best drug in the world, but if patients can't afford it and they can't get it, then it won't be effective," said study author Dr. Greg Knight. He is chief fellow with the University of North Carolina School of Medicine's division of hematology and oncology. "We saw a significant portion of patients in our study who were stretching their prescriptions or not coming to the doctor's office," Knight said in a university news release. The researchers reviewed survey results from nearly 2,000 patients at the N.C. Cancer Hospital in Chapel Hill, N.C. The participants were all 18 and older, and had been ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Gleevec, Votrient, Brain Tumor, Avastin, Tarceva, Melanoma, Skin Cancer, Ovarian Cancer, Nausea/Vomiting - Chemotherapy Induced, Tasigna, Endometrial Cancer, Sutent, Sprycel, Herceptin, Afinitor

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Lung Cancer, Colorectal Cancer, Gleevec, Rituxan, Isotretinoin, Zoladex

FDA Approves Lenvima (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy

Posted 16 May 2016 by Drugs.com

WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ – Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy. This approval was based on the impressive results of the registration study (Study 205), in which the once daily combination of 18 mg Lenvima and 5 mg everolimus demonstrated a substantial improvement in progression-free survival (PFS), powerful objective response rate (ORR) and clinically meaningful overall survival (OS) when compared with everolimus alone, a standard of care for patients with aRCC who have received prior anti-angiogenic therapy. "Lenvatinib plus everolimus is the first and only FDA-approved ... Read more

Related support groups: Renal Cell Carcinoma, Lenvima, Lenvatinib

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Tretinoin, Femara, Lupron Depot, Lung Cancer, Colorectal Cancer, Rituxan, Gleevec, Renal Cell Carcinoma

FDA Approves Lenvima (lenvatinib) for Advanced Thyroid Cancer

Posted 16 Feb 2015 by Drugs.com

FRIDAY, Feb. 13, 2015 – The U.S. Food and Drug Administration on Friday approved a new drug to treat progressive thyroid cancer that continues to worsen despite radioactive iodine therapy. Results of a just-published clinical trial found that the oral drug Lenvima (lenvatinib) delayed progression of the disease almost five times longer than a placebo in people with recurring tumors. Lenvima is a targeted therapy that fights thyroid cancer by deterring the growth of new blood vessels that could help feed the cancer, researchers said. It delayed progression of advanced thyroid cancer by 18 months, compared with four months for patients treated with a placebo, the trial found. Results of the study, which was funded by drug manufacturer Eisai, were published in the Feb. 12 issue of the New England Journal of Medicine. Historically, radioactive iodine has been the only treatment available ... Read more

Related support groups: Thyroid Cancer, Lenvatinib

Ask a Question

Further Information

Related Condition Support Groups

Renal Cell Carcinoma, Thyroid Cancer

Related Drug Support Groups

Lenvima

Lenvatinib Patient Information at Drugs.com